Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A Phase II Study of Telisotuzumab Vedotin in Patients With c–MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)

Clinical Lung Cancer(2020)10.1016/j.cllc.2020.09.013Source: DataRank Database

A Phase II Study of Telisotuzumab Vedotin in Patients With c–MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753) is a research paper published in Clinical Lung Cancer (2020). On theSindex it has a DataRank of 2.3. It has been cited 79 times, with 74 citing works in its 1-hop citation network.

N/A

2.3DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access79 citations · 74 citing works in its network

Download PDF

Cite:

Linked data & code

nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT03574753

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (53 grants)OA: greenTopics (24)IDs (PubMed, PMC)Annotations (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 28%Citation Network 72%

Base Score Contribution

0.657

From this paper's citation signal

Citation Network Contribution

1.7

From 66 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 74 citers.

Durable response to amivantamab in treatment refractory NSCLC harboring EGFR and complex MET mutations: A case report
Lung Cancer20233 citations13 referencesContributes 0.107
Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer
Journal of Clinical Oncology202350 citations45 referencesContributes 0.087
MYTX-011: A pH-Dependent Anti–c-MET Antibody–Drug Conjugate Designed for Enhanced Payload Delivery to c-MET–Expressing Tumor Cells
Molecular Cancer Therapeutics202414 citations32 referencesContributes 0.085
Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer
Lung Cancer202185 citations64 referencesContributes 0.070
Telisotuzumab vedotin with erlotinib in the treatment of non-small cell lung cancer: a well MET combination?
Translational Lung Cancer Research20233 citations21 referencesContributes 0.066

Authors (17)

Mary W. Redman ORCID,Susanne M. Arnold ORCID,Fred R. Hirsch ORCID,Philip C. Mack ORCID,Lawrence H. Schwartz ORCID

Live enrichment

PubMed:33221175 PMC:PMC8044254

National Cancer Institute

Grant: CA180819

National Cancer Institute

Grant: CA180820

National Cancer Institute

Grant: CA180821

National Cancer Institute

Grant: CA180828

National Cancer Institute

Grant: CA180868

National Cancer Institute

Grant: CA180888

National Cancer Institute

Grant: CA189804

National Cancer Institute

Grant: CA189808

National Cancer Institute

Grant: CA189830

National Cancer Institute

Grant: CA189858

National Cancer Institute

Grant: CA189873

National Cancer Institute

Grant: CA189952

National Cancer Institute

Grant: CA189958

National Cancer Institute

Grant: CA189971

National Cancer Institute

Grant: CA189997

National Cancer Institute

Grant: CA239767

NCI NIH HHS

Grant: U10 CA180820

NCI NIH HHS

Grant: UG1 CA189808

NCI NIH HHS

Grant: UG1 CA189997

NCATS NIH HHS

Grant: UL1 TR001863

NCI NIH HHS

Grant: U10 CA180819

NCI NIH HHS

Grant: UG1 CA189858

NCI NIH HHS

Grant: UG1 CA233340

NCI NIH HHS

Grant: UM1 CA186704

NCI NIH HHS

Grant: U10 CA180868

NCI NIH HHS

Grant: U10 CA180828

NCI NIH HHS

Grant: UG1 CA189971

NCI NIH HHS

Grant: UG1 CA239767

NCI NIH HHS

Grant: U10 CA180821

NCI NIH HHS

Grant: UG1 CA233339

NCI NIH HHS

Grant: P30 CA093373

NCI NIH HHS

Grant: UG1 CA189804

NCI NIH HHS

Grant: UG1 CA189873

NCI NIH HHS

Grant: UG1 CA189952

NCI NIH HHS

Grant: U10 CA180888

NCI NIH HHS

Grant: UG1 CA189830

NCI NIH HHS

Grant: UG1 CA189958

AstraZeneca

Shire

Eli Lilly and Company

AbbVie

F. Hoffmann-La Roche

Boehringer Ingelheim

Bristol-Myers Squibb Canada

Spectrum Pharmaceuticals

Merck

Neos Therapeutics

Novartis

National Institutes of Health

Clovis Oncology

Exelixis

Takeda Pharmaceuticals U.S.A.

University of Colorado

greenLicense: https://www.elsevier.com/legal/tdmrep-license

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8044254

publisherhttps://api.elsevier.com/content/article/PII:S152573042030293X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S152573042030293X?httpAccept=text/plain

MeSH Terms

HumansCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellLung NeoplasmsNeoplasm Recurrence, LocalPneumoniaAntineoplastic AgentsAntibodies, MonoclonalNeoplasm StagingTreatment OutcomeSurvival RateCohort StudiesAgedAged, 80 and overMiddle AgedFemaleMaleProto-Oncogene Proteins c-metProgression-Free Survival

Keywords

Squamous cell carcinomac-MetAntibody-drug ConjugateLung-mapTelisotuzumab Vedotin